Boston Scientific price target raised to $52 from $50 at Stifel

Stifel analyst Rick Wise raised the firm’s price target on Boston Scientific to $52 from $50 and keeps a Buy rating on the shares. While the surprising Italian "payment provision" optics complicated the company’s Q4 reported performance, organic performance was "excellent" across all product lines, the analyst tells investors in a research note. The firm added that Boston Scientific has important product launches and multiple potentially-positive data catalysts ahead, and that such factors along with possibly easing macro pressures could help prove initial 2023 guidance conservative.